|
|
Mologen AG - Comparative Business Analysis Snapshot
Business Description
Mologen AG. The Group's principal activity is researching and developing deoxyribonucleic acid (DNA)-based drugs for diseases that require a high degree of medical treatment. The Group's activities concentrate on creating new and improving existing immunological drugs and therapies to combat cancer and developing vaccines for the prevention and treatment of serious infectious diseases in humans, as well as animals. Two core areas of the Group's operations are the treatment of cancer and infectious diseases. The Group developed and patented the DNA-based platform technologies MIDGE as well as dSLIM which provide the basis for prophylactic and therapeutic applications for treatment of diseases, represented by a range of cancer therapy solutions. The Group was involved in the first clinical trials in human gene therapy in Germany. The Group also has commercial facilities in Berlin, Madrid and Spain.
Competitor Analysis
This analysis compares Mologen AG with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
